In the context of ICI after liver transplantation, a retrospective study investigated intragraft PD-L1 expression as a marker of acute transplant rejection risk in liver-transplanted patients with recurrent HCC who underwent anti-PD-1 therapy (19). The gene discussed is CD274; the disease is hepatocellular carcinoma.